journal article·2026-06Open access

Dual-targeted manganese-doped carbon dots activate the cGAS–STING pathway and immunogenic cell death for potent glioblastoma immunotherapy

Zhen Li, Changshui Yu, Hongyu Che, Duo Xu, Dong Lu, Yan Wang, Xingjun Li, Shuo Ma, Xu Zhang, Zhengkui Zhang, Rutong Yu

Abstract

Glioblastoma (GBM) remains poorly responsive to immunotherapy due to restricted brain delivery and a profoundly immunosuppressive "cold" microenvironment. Here, we report ultrasmall manganese-doped carbon dots enriched with surface amino and carboxyl groups (Mn-CDs) as a self-adjuvanted nanotherapeutic that integrates dual targeting with a synergistic immune cascade. Mn-CDs exploit LAT1-mediated transport to traverse the blood-brain barrier and preferentially accumulate in glioma tissue, while their intrinsic positive surface potential drives mitochondrial tropism via the mitochondrial membrane potential. Once localized to mitochondria, mixed-valence Mn centers catalyze Fenton-like reactions, amplifying oxidative stress and inducing mitochondrial depolarization and ultrastructural disruption. This organelle-localized stress is coupled to robust activation of the cGAS-STING-TBK1-IRF3 axis, leading to elevated IFN-I signaling and proinflammatory chemokine production. In parallel, Mn-CDs elicit immunogenic cell death, as evidenced by calreticulin (CRT) exposure, HMGB1 release, and extracellular ATP emission, thereby promoting dendritic cell maturation and cytotoxic T-cell infiltration. In orthotopic syngeneic GBM models, Mn-CDs remodel the immunosuppressive tumor microenvironment, suppress intracranial tumor progression, and prolong survival with favorable biosafety. Collectively, this work establishes a dual-targeted Mn-based carbon nanoplatform that converts GBM toward an immune-responsive state through convergent cGAS-STING activation and ICD-driven immune priming.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Inflammasome and immune disorders · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial10.1016/S1470-2045(09)70025-7 ↗
3. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma10.1056/NEJMoa043330 ↗
4. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
5. The blood-brain barrier bottleneck in brain drug development10.1602/neurorx.2.1.3 ↗
6. The microenvironmental landscape of brain tumors10.1016/j.ccell.2017.02.009 ↗
7. Current state of immunotherapy for glioblastoma10.1038/s41571-018-0003-5 ↗
8. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial10.1001/jamaoncol.2020.1024 ↗
9. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma10.1038/s41591-018-0337-7 ↗
10. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma10.1038/s41591-018-0339-5 ↗
11. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling10.1038/nature07317 ↗
12. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway10.1126/science.1232458 ↗
13. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA10.1126/science.1229963 ↗
14. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING10.1038/nature12306 ↗
15. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling10.1016/j.molcel.2014.03.040 ↗
16. STING: infection, inflammation and cancer10.1038/nri3921 ↗
17. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors10.1016/j.immuni.2014.10.017 ↗
18. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs10.1038/nchembio.1661 ↗
19. Mitochondrial DNA in inflammation and immunity10.15252/embr.201949799 ↗
20. Mitochondrial DNA stress primes the antiviral innate immune response10.1038/nature14156 ↗
21. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses10.1016/j.immuni.2018.03.017 ↗
22. Chemodynamic therapy: tumour microenvironment-mediated Fenton and Fenton-like reactions10.1002/anie.201805664 ↗
23. Manganese: recent advances in understanding its transport and neurotoxicity10.1016/j.taap.2007.03.001 ↗
24. Tumor microenvironment-responsive manganese-based nano-modulator activate the cGAS-STING pathway to enhance innate immune system response10.1186/s12951-024-02809-6 ↗
25. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy10.1038/s41422-020-00395-4 ↗
26. Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids10.1038/s41551-020-0540-y ↗
27. Luminescent carbon nanodots: emergent nanolights10.1002/anie.200906623 ↗
28. Targeting lipophilic cations to mitochondria10.1016/j.bbabio.2008.03.029 ↗
29. Drug transport across the blood-brain barrier10.1038/jcbfm.2012.126 ↗
30. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
31. Selective expression of the large neutral amino acid transporter at the blood-brain barrier10.1073/pnas.96.21.12079 ↗
32. Renal clearance of quantum dots10.1038/nbt1340 ↗
33. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
34. Dendritic cells and the control of immunity10.1038/32588 ↗
35. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
36. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition10.1016/j.ccell.2022.04.009 ↗
37. Carbon dots nanophotosensitizers with tunable reactive oxygen species generation for mitochondrion-targeted type I/II photodynamic therapy10.1016/j.biomaterials.2022.121953 ↗
38. Manganese oxide nanomaterials: synthesis, properties, and theranostic applications10.1002/adma.201905823 ↗
39. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?10.1016/j.semcancer.2005.04.005 ↗
40. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms10.1111/j.1349-7006.2008.00969.x ↗
41. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
42. Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma10.1172/JCI178628 ↗
43. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
44. STING activation in cancer immunotherapy10.7150/thno.37574 ↗
45. Microenvironmental regulation of tumor progression and metastasis10.1038/nm.3394 ↗
46. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy10.7150/thno.49577 ↗
47. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets10.1021/ja801482d ↗
48. Manganese salts function as potent adjuvants10.1038/s41423-021-00669-w ↗
49. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗